LIGHT CHAIN (AL) AMYLOIDOSIS
Clinical trials for LIGHT CHAIN (AL) AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new LIGHT CHAIN (AL) AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for LIGHT CHAIN (AL) AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a targeted drug trio tame a rare amyloid disease?
Disease control OngoingThis phase 2 trial is testing whether combining daratumumab, venetoclax, and dexamethasone can produce a deep and rapid response in people newly diagnosed with light-chain (AL) amyloidosis who carry a specific genetic marker called t(11;14). The study enrolls 36 participants and …
Matched conditions: LIGHT CHAIN (AL) AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Engineered immune cells take aim at a rare Protein-Clogging disease
Disease control OngoingThis study tests a new treatment called NXC-201 CAR-T for people with AL amyloidosis, a rare disease where abnormal proteins build up in organs. The therapy uses a patient's own immune cells, modified to target and destroy the cells producing these proteins. The trial is open to …
Matched conditions: LIGHT CHAIN (AL) AMYLOIDOSIS
Phase: PHASE1, PHASE2 • Sponsor: Nexcella Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New chemo formula aims to boost transplant success in blood cancers
Disease control OngoingThis study tests a new, more stable version of the chemotherapy drug melphalan in people with multiple myeloma or AL amyloidosis who are getting a stem cell transplant. The goal is to find the best dose that reaches a target level in the body, while possibly causing fewer side ef…
Matched conditions: LIGHT CHAIN (AL) AMYLOIDOSIS
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC